ZBTB11-AS1: A Potential Disease Biomarker and Drug Target (G100009676)

Target Name: ZBTB11-AS1

NCBI ID: G100009676

ZBTB11-AS1

Other Name(s): ZBTB11 antisense RNA 1

ZBTB11-AS1: A Potential Disease Biomarker and Drug Target

Abstract
ZBTB11-AS1, also known as Zinc Finger and BTB Domain-Containing 11 Antisense RNA 1, is a long non-coding RNA (lncRNA) that has recently gained attention as a potential disease biomarker and drug target. In this article, we explore the role of ZBTB11-AS1 in various diseases and its potential as a therapeutic target. We discuss the underlying mechanisms by which ZBTB11-AS1 exerts its effects and the current research efforts focused on targeting this lncRNA for therapeutic interventions. Understanding the significance of ZBTB11-AS1 in disease progression could pave the way for innovative diagnostic techniques and effective treatments.

ZBTB11-AS1: An Overview

ZBTB11-AS1, located on chromosome 19q13.2, is a non-protein coding RNA molecule that is transcribed from the opposite strand of the ZBTB11 gene. It serves as a regulator of gene expression through various molecular mechanisms, including chromatin modification and post-transcriptional regulation. Although lncRNAs were initially considered junk molecules, recent research has highlighted their crucial roles in various biological processes and disease states.

ZBTB11-AS1 and Cancer

1. ZBTB11-AS1 as a Diagnostic Biomarker in Cancer
ZBTB11-AS1 has emerged as a potential diagnostic biomarker in several types of cancer. Its dysregulation has been observed in lung, breast, colorectal, and gastric cancers, among others. High expression levels of ZBTB11-AS1 have been associated with poor prognosis and advanced tumor stages, indicating its potential as a diagnostic tool for early cancer detection.

2. The Role of ZBTB11-AS1 in Cancer Progression
ZBTB11-AS1 has been implicated in cancer progression by promoting cell proliferation, invasion, and metastasis. It has been shown to interact with key signaling pathways involved in tumorigenesis, such as the Wnt/尾-catenin pathway. Furthermore, ZBTB11-AS1 can modulate the expression of oncogenes and tumor suppressor genes, contributing to the aggressive behavior of cancer cells.

ZBTB11-AS1 in Neurological Disorders

1. Association with Neurodegenerative Diseases
Emerging evidence suggests that ZBTB11-AS1 may play a role in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Aberrant expression of ZBTB11-AS1 has been observed in brain tissues of patients, and its dysregulation has been linked to neuronal dysfunction, neuroinflammation, and impaired cellular pathways involved in protein homeostasis.

2. ZBTB11-AS1 as a Potential Therapeutic Target in Neurological Disorders
Therapeutic interventions aiming to modulate ZBTB11-AS1 expression could provide a novel approach in the treatment of neurodegenerative disorders. Targeting ZBTB11-AS1 could potentially restore proper neuronal function and alleviate disease progression, making it an attractive drug target in this context.

Targeting ZBTB11-AS1 for Therapeutic Interventions

1. siRNA and Antisense Oligonucleotides
Silencing ZBTB11-AS1 using small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) has shown promising results in preclinical studies. These approaches effectively downregulate the expression of ZBTB11-AS1 and inhibit tumor growth in cancer models, suggesting their potential therapeutic applications.

2. Small Molecules
Identification and development of small molecule inhibitors targeting ZBTB11-AS1 directly or its interacting partners may offer another avenue for therapeutic intervention. High-throughput screening and in silico approaches could potentially aid in the discovery of these small molecules, enhancing our ability to modulate ZBTB11-AS1 expression or function.

The Future of ZBTB11-AS1 Research

The study of ZBTB11-AS1 is still in its early stages, and much remains to be explored. Further investigations are required to fully elucidate the molecular mechanisms by which ZBTB11-AS1 functions and its precise role in disease pathogenesis. Understanding its interactions with other molecules and signaling pathways could provide valuable insights into its therapeutic potential in various diseases.

Conclusion

ZBTB11-AS1 is emerging as a promising disease biomarker and potential drug target. Its dysregulation has been observed in numerous diseases, particularly in cancer and neurological disorders. Modulating ZBTB11-AS1 expression or function through various therapeutic strategies holds great promise for developing innovative diagnostic techniques and effective treatments. Continued research efforts focused on ZBTB11-AS1 will undoubtedly shed light on its significance in disease progression, leading to improved patient outcomes in the future.

Protein Name: ZBTB11 Antisense RNA 1

The "ZBTB11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB11-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets